Skip to main content

Table 3 GI symptoms in relation to genotype in patients with TTR mutations

From: THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease

Symptom

V30M

Non-V30M

p value

n = 792

n = 252

Any GI symptom

547 (69.3%)

130 (56.0%)

<0.001

Early satiety

242 (30.7%)

44 (19.0%)

<0.001

Nausea

150 (19.0%)

35 (15.1%)

0.172

Vomiting

125 (15.8%)

22 (9.5%)

0.016

Constipation

178 (22.6%)

41 (17.7%)

0.117

Diarrhea/constipation

225 (28.6%)

42 (18.1%)

0.001

Diarrhea

174 (22.1%)

42 (18.2%)

0.199

Fecal incontinence

57 (7.2%)

11 (4.8%)

0.186

Unintentional weight loss

272 (34.6%)

70 (30.3%)

0.224

  1. Number of patients, n (%), reporting gastrointestinal (GI) symptoms at enrollment. The TTR V122I, I68L and L111M mutations (mainly associated with cardiac complications) were excluded from the non-V30M group.